The Hydration Pharmaceuticals Co (ASX:HPC) EBIT: A$-4.17 Mil (TTM As of Dec. 2025)


What is The Hydration Pharmaceuticals Co EBIT?

The Hydration Pharmaceuticals Co ASX:HPC -20.00% EBIT is A$-4.17 Mil as of Dec. 2025. The stock has 3 warning signs investors should review.

The Hydration Pharmaceuticals Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was A$-2.50 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-4.17 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. The Hydration Pharmaceuticals Co's annualized ROC % for the quarter that ended in Dec. 2025 was -751.24%. The Hydration Pharmaceuticals Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -932.22%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. The Hydration Pharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -65.13%.

The Hydration Pharmaceuticals Co  (ASX:HPC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

The Hydration Pharmaceuticals Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-6.194 * ( 1 - 0% )/( (0.882 + 0.767)/ 2 )
=-6.194/0.8245
=-751.24 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.946 - 0.946 - ( 2.118 - max(0, 1.207 - 3.946+2.118))
=0.882

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.3 - 0.849 - ( 1.684 - max(0, 1.165 - 3.3+1.684))
=0.767

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

The Hydration Pharmaceuticals Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5.006/( ( (0 + max(0.621, 0)) + (0 + max(0.453, 0)) )/ 2 )
=-5.006/( ( 0.621 + 0.453 )/ 2 )
=-5.006/0.537
=-932.22 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.276 + 1.009 + 0.543) - (0.946 + 0 + 0.261)
=0.621

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.122 + 1.315 + 0.181) - (0.849 + 0 + 0.316)
=0.453

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

The Hydration Pharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-4.174/6.409
=-65.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The Hydration Pharmaceuticals Co EBIT Related Terms

The Hydration Pharmaceuticals Co EBIT Historical Data

* Premium members only.

The historical data trend for The Hydration Pharmaceuticals Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The Hydration Pharmaceuticals Co EBIT Chart

The Hydration Pharmaceuticals Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
-7.45 -15.59 -11.14 -6.18 -4.14

The Hydration Pharmaceuticals Co Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only -7.97 -2.24 -3.83 -1.67 -2.50

ASX:HPC vs SYY, USFD, PFGC: EBIT Comparison

For the Food Distribution subindustry, The Hydration Pharmaceuticals Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

The Hydration Pharmaceuticals Co EV-to-EBIT vs Retail - Defensive Industry

For the Retail - Defensive industry and Consumer Defensive sector, The Hydration Pharmaceuticals Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where The Hydration Pharmaceuticals Co's EV-to-EBIT falls into.


The Hydration Pharmaceuticals Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-4.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of A$-4.17 Mil mean?
The Hydration Pharmaceuticals Co (ASX:HPC) has a EBIT of A$-4.17 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on The Hydration Pharmaceuticals Co.
Is The Hydration Pharmaceuticals Co's EBIT too high?
The Hydration Pharmaceuticals Co's current EBIT is A$-4.17 Mil.
How does The Hydration Pharmaceuticals Co's EBIT compare to SYY and USFD?
The Hydration Pharmaceuticals Co's EBIT of A$-4.17 Mil can be compared against companies in the Retail - Defensive industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Retail - Defensive company?
A good EBIT depends on the Retail - Defensive industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on The Hydration Pharmaceuticals Co. The Hydration Pharmaceuticals Co's current EBIT is A$-4.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Hydration Pharmaceuticals Co stock overvalued right now?
The Hydration Pharmaceuticals Co (ASX:HPC) has a current EBIT of A$-4.17 Mil. The current EBIT is A$-4.17 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For The Hydration Pharmaceuticals Co (ASX:HPC), the current EBIT is A$-4.17 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

The Hydration Pharmaceuticals Co Business Description

Address 6 Palmer Parade, Level 2, Cremorne, Melbourne, VIC, AUS, 3121
The Hydration Pharmaceuticals Co Ltd is a consumer products company that markets and sells a range of liquid, tablet and powder Healthy Hydration Solutions products into the USA market, under the Hydralyte brand. Hydralyte collates and translates consumer insights and needs into developing and delivering quality hydration products to market. The Company's business model is an asset light, flexible production model that allows it to outsource manufacturing and packaging to appropriate suppliers.